Last reviewed 2026-05-24 · How we verify

chemoimmunothrapy

Zhejiang University · Phase 2 active Small molecule ✓ Verified May 2026

chemoimmunothrapy is a Small molecule drug developed by Zhejiang University. It is currently in Phase 2 development.

Chemoimmunotherapy is a treatment approach that combines chemotherapy with immunotherapy, as seen in clinical trials for non-small cell lung cancer (NSCLC) such as NCT06962189. This treatment has been studied in patients with unresectable Stage IIIB-IIIC NSCLC, with the goal of evaluating its efficacy and safety.

Likelihood of approval

16.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Immunology slight uplift +1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	chemoimmunothrapy
Sponsor	Zhejiang University
Modality	Small molecule
Therapeutic area	Immunology
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

The Efficacy and Safety of Sintilimab Plus Chemotherapy in Surgical Conversion for Patients With Unresectable Stage IIIB-IIIC NSCLC: A Prospective, Single-Arm, Phase II Study (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

chemoimmunothrapy CI brief — competitive landscape report
chemoimmunothrapy updates RSS · CI watch RSS
Zhejiang University portfolio CI

Frequently asked questions about chemoimmunothrapy

What is chemoimmunothrapy?

chemoimmunothrapy is a Small molecule drug developed by Zhejiang University.

Who makes chemoimmunothrapy?

chemoimmunothrapy is developed by Zhejiang University (see full Zhejiang University pipeline at /company/zhejiang-university).

What development phase is chemoimmunothrapy in?

chemoimmunothrapy is in Phase 2.

Manufacturer: Zhejiang University — full pipeline
Therapeutic area: All drugs in Immunology

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing